Invokana and Other SGLT2 Inhibitors Might Double the Risk of Diabetic Ketoacidosis (DKA)
By Karissa Klotsche on November 13, 2017
FDA Invokana Diabetic Ketoacidosis Warnings
Invokana is Johnson & Johnson’s brand name for Canagliflozin which was approved by the FDA in March 2013. Invokana and other SGLT2 inhibitors (Sodium-glucose contransporter-2 inhibitor) lower blood sugar by causing the kidneys to excrete glucose through the patient’s urine, reducing the amount of glucose in the patient’s blood. However, crucial blood components have also been found to excrete from the patient’s kidneys as well, allegedly leading to severe side effects and complications.
Ketoacidosis is a serious, potentially life-threatening medical condition in which the patient’s body cannot properly metabolize blood acids (ketones). Ketone buildups may cause the blood’s pH to drop to unsafe levels, possibly resulting in diabetic coma or death if the condition is left untreated.
The 8-week study consisted of following 351 Type 1 Diabetes patients who were between the ages of 25 and 65. Participants were given either placebo, 100 mg or 300 mg doses of Invokana. No one in the placebo group developed diabetic ketoacidosis while five of the 100 mg participants and seven 300 mg participants developed the condition.
In June 2016, the FDA required additional label warnings about the link between Invokana and kidney risks, highlighting that the medication may increase the risk of acute kidney injury.
In December 2015, the FDA required Johnson & Johnson to add new diabetic ketoacidosis warnings to Invokana, emphasizing that the medication significantly increases the risk of this potentially deadly condition.
It is important to know that if Diabetic ketoacidosis (DKA) is not treated, it can lead to severe illness or death. In more detail, possible complications of DKA include these medical conditions:
- Cerebral Edema (fluid buildup in the brain)
- Bowel Necrosis (death of bowel tissue due to low blood pressure)
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed Diabetic ketoacidosis (DKA).
Call To Start Your Claim… (877) 963-2806